FORMULATIONS FOR REDUCING NEURONAL DEGENERATION

• US 20120252750A1
• Filed: 04/02/2012
• Published: 10/04/2012
• Est. Priority Date: 07/25/2003
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: SHEA, Thomas B., NICOLOSI, Robert J., ROGERS, Eugene
• Application Number:
  US13/437,487
• Publication Number:
  US 20120252750A1
• Time in Patent Office: Days
• US Class Current: 514/46
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/0612 Carnitine
• CPC Class Codes: A23V 2250/704 Vitamin B
• CPC Class Codes: A23V 2250/712 Vitamin E
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer'"'"'s disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).

Claims

1. A method for treating a neurodegenerative disorder in a mammal, the method comprising administering to the mammal an amount of a formulation effective to reduce a level of reactive oxygen species (ROS) in an in vitro neural cell culture, wherein the formulation comprises, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms.

2. The method of claim 1, wherein the formulation comprises folate, vitamin E, ALCAR, NAC, and SAM.

3. The method of claim 1, wherein the mammal suffers from a neurodegenerative disorder selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, or amyotrophic lateral sclerosis (ALS).

4. The method of claim 1, wherein the mammal is a human.

5. The method of claim 1, wherein a level of reactive oxygen species (ROS) in the mammal is reduced compared to a reference.

6. A composition comprising, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition reduces a level of reactive oxygen species (ROS) in an in vitro neural cell culture.

7. The composition of claim 6, wherein the composition comprises folate, vitamin E, ALCAR, NAC, and SAM.

26. The composition of claim 6, wherein the unit dose comprises about 200-2000 μ

g folate.

27. The composition of claim 6, wherein the unit dose comprises about 50-3000 I.U. vitamin E.

28. The composition of claim 6, wherein the unit dose comprises about 200-4000 mg ALCAR.

29. The composition of claim 6, wherein the unit dose comprises about 200-2000 mg NAC.

30. The composition of claim 6, wherein the unit dose comprises about 400-2000 mg SAM.

31. The composition of claim 6, wherein the unit dose comprises about 20-500 mg DZA.

32. The composition of claim 7, wherein the unit dose comprises about 200-2000 μ

g folate, about 50-3000 I.U. vitamin E, about 200-4000 mg ALCAR, about 200-2000 mg NAC, and about 400-2000 mg SAM.

33. The composition of claim 7, wherein the unit dose comprises about 400-1500 μ

g folate, about 50 I.U. vitamin E, about 500-3000 mg ALCAR, about 500-1500 mg NAC, and about 400-1500 mg SAM.

34. The composition of claim 7, wherein the unit dose of the composition comprises about 200-2000 μ

g folate, about 200-4000 mg ALCAR, about 400-2000 mg SAM, and about 200-2000 mg NAC.

35. The composition of claim 7, wherein the unit dose of the composition comprises about 400-1500 μ

g folate, about 500-3000 mg ALCAR, about 400-1500 mg SAM, and about 500-1500 mg NAC.

37. A method of improving memory in a subject, comprising administering a composition of any one of claim 6, 7, or 26-35 to the subject, such that memory is improved.

8-25. -25. (canceled)

36. A composition comprising folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition improves memory in a subject.